MRK Jun 2024 150.000 call
- Yahoo Finance Video
How Medicare drug price negotiations could hit pharma stocks
As a string of negative headlines and promising new developments present ideal buying opportunities for investors, Josh Lipton and Julie Hyman perform a mid-year check on the pharmaceutical industry. Goldman Sachs senior biotechnology analyst Chris Shibutani joins Market Domination to break down the health of the pharmaceutical large-caps and unrecognized areas of opportunity in the sector. Shibutani says the industry is "quite healthy," but acknowledges there are always "cross currents." He points to "tremendous advancements" in biotechnology innovation rising to daunting unmet needs, from cancer to cardiovascular disease. The analyst points to "holy grail-like" opportunities such as obesity drugs, and notes improvements in chemotherapy and next-generation antibody-drug conjugates for cancer treatment. However, Shibutani explains that the Inflation Reduction Act may challenge the industry, as the landmark legislation stipulates drug price negotiation for Medicare that is "beginning to play out." For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This article was written by Gabriel Roy
- Benzinga
What's Going On With Merck Stock On Friday?
On Thursday, the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) unanimously voted to recommend Merck & Co Inc’s (NYSE:MRK) Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) for adults 65 years of age and older. It is also commonly known as the pneumonia vaccine. Specifically, the ACIP voted to recommend a single dose of Capvaxive for: Adults 65 years and older who have not previously received a pneumococcal conjugate vaccine or wh
- Zacks
Merck's (MRK) New Pneumococcal Jab Capvaxive Gets CDC Panel Vote
Merck's (MRK) vaccine, Capvaxive, gets unanimous recommendation by a CDC committee for adults aged 65 years and older for pneumococcal vaccination and those with certain other underlying conditions.
